You are here

Article Text

Article menu

Download PDFPDF

Scientific Abstracts
POSTERS only
Vasculitis – large vessel vasculitis
POS0804 TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: MULTICENTRIC OBSERVATIONAL COMPARATIVE STUDY
Free
  1. D. Prieto-Peña1,
  2. J. Loricera1,
  3. S. Castañeda2,
  4. C. Moriano3,
  5. P. Bernabéu4,
  6. P. Vela-Casasempere4,
  7. J. Narváez5,
  8. V. Aldasoro6,
  9. O. Maíz7,
  10. C. Fernández-López8,
  11. M. Freire González8,
  12. R. Melero9,
  13. I. Villa-Blanco10,
  14. B. González-Alvarez11,
  15. R. Solans-Laqué12,
  16. J. L. Callejas-Rubio13,
  17. C. Fernández-Díaz2,
  18. E. Rubio Romero14,
  19. S. García Morillo14,
  20. M. Minguez15,
  21. C. Fernández-Carballido15,
  22. E. De Miguel16,
  23. J. Sanchez-Martin17,
  24. E. Fernández18,
  25. S. Melchor17,
  26. E. Salgado-Pérez19,
  27. B. Bravo20,
  28. S. Romero-Yuste21,
  29. E. Galíndez-Agirregoikoa22,
  30. F. Sivera23,
  31. I. Ferraz-Amaro24,
  32. C. Hidalgo25,
  33. C. Romero-Gómez26,
  34. C. Galisteo27,
  35. P. Moya28,
  36. N. Alvarez-Rivas29,
  37. J. Mendizabal6,
  38. J. C. Nieto González30,
  39. J. R. De Dios31,
  40. J. L. Andreu32,
  41. I. Pérez de Pedro33,
  42. M. Revenga34,
  43. J. L. Alonso Valdivieso35,
  44. R. M. Rosa36,
  45. I. De la Morena37,
  46. N. Fernández-Llanio38,
  47. E. Labrador39,
  48. J. A. Roman-Ivorra40,
  49. F. Ortiz-Sanjuán40,
  50. A. García-Valle41,
  51. A. Gallego42,
  52. C. Iñiguez43,
  53. N. Garrido-Puñal14,
  54. R. De la Torre44,
  55. R. López-González45,
  56. P. Collado46,
  57. E. Raya13,
  58. F. Navarro47,
  59. A. J. Mas48,
  60. C. Ordás49,
  61. M. D. Boquet38,
  62. M. L. Velloso Feijoo50,
  63. C. Campos Fernández51,
  64. I. Rúa-Figueroa52,
  65. A. Conesa53,
  66. S. Manrique Arija26,
  67. M. A. González-Gay1,
  68. R. Blanco1
  1. 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Rheumatology, Santander, Spain
  2. 2H. Universitario de La Princesa, Rheumatology, Madrid, Spain
  3. 3Hospital Universitario de León, Rheumatology, León, Spain
  4. 4Hospital General de Alicante, Rheumatology, Alicante, Spain
  5. 5Hospital de Bellvitge, Rheumatology, Barcelona, Spain
  6. 6Complejo Hospitalario de Navarra, Rheumatology, Pamplona, Spain
  7. 7Hospital Univesitario de Donostia, Rheumatology, San Sebastián, Spain
  8. 8Complejo H. Universitario de A Coruña, Rheumatology, A Coruña, Spain
  9. 9Complejo H. De Vigo, Rheumatology, Vigo, Spain
  10. 10Hospital Sierrallana, Rheumatology, Torrelavega, Spain
  11. 11Hospital Nuestra Señora de la Candelaria, Rheumatology, Tenerife, Spain
  12. 12Hospital Vall d’Hebron, Internal Medicine, Barcelona, Spain
  13. 13Hospital San Cecilio, Rheumatology, Granada, Spain
  14. 14Hospital Virgen del Rocío, Rheumatology, Sevilla, Spain
  15. 15Hospital San Juan de Alicante, Rheumatology, Alicante, Spain
  16. 16Hospital Universitario La Paz, Rheumatology, Madrid, Spain
  17. 17Hospital Universitario 12 de Octubre, Rheumatology, Madrid, Spain
  18. 18H. Virgen de Arrixaca, Rheumatology, Murcia, Spain
  19. 19Complejo H. Universitario de Ourense, Rheumatology, Ourense, Spain
  20. 20Hospital Virgen de las Nieves, Rheumatology, Granada, Spain
  21. 21Complejo H. Universitario de Pontevedra, Rheumatology, Pontevedra, Spain
  22. 22Hospital de Basurto, Rheumatology, Bilbao, Spain
  23. 23Hospital Universitario de Elda, Rheumatology, Alicante, Spain
  24. 24Hospital Universitario de Canarias, Rheumatology, Tenerife, Spain
  25. 25Complejo Universitario de Salamanca, Rheumatology, Salamanca, Spain
  26. 26Hospital Regional de Málaga, Rheumatology, Malaga, Spain
  27. 27Hospital Parc Tauli, Rheumatology, Sabadel, Spain
  28. 28Hospital Sant Pau, Rheumatology, Barcelona, Spain
  29. 29Hospital Universitario San Agustín, Rheumatology, Avilés, Spain
  30. 30Hospital Gregorio Marañon, Rheumatology, Madrid, Spain
  31. 31Hospital de Araba, Rheumatology, Mondragón, Spain
  32. 32Hospital Puerta de Hierro, Rheumatology, Madrid, Spain
  33. 33Hospital Carlos Haya, Rheumatology, Malaga, Spain
  34. 34Hospital Ramón y Cajal, Rheumatology, Madrid, Spain
  35. 35Hospital Universitario de Burgos, Rheumatology, Burgos, Spain
  36. 36Hospital Universitario Reina Sofía, Rheumatology, Cordoba, Spain
  37. 37Hospital Clinico Universitario de Valencia, Rheumatology, Valencia, Spain
  38. 38Hospital Arnau de Vilanova, Rheumatology, Valencia, Spain
  39. 39Hospital San Pedro, Rheumatology, Logroño, Spain
  40. 40Hospital Universitario y Politécnico La Fe, Rheumatology, Valencia, Spain
  41. 41Completo Asistencial Palencia, Rheumatology, Palencia, Spain
  42. 42Hospital Universitario de Badajoz, Rheumatology, Badajoz, Spain
  43. 43Hospital Lucus Augusti, Rheumatology, Lugo, Spain
  44. 44Hospital Universitario Central de Asturias, Internal Medicine, Oviedo, Spain
  45. 45Complejo Hospitalario de Zamora, Rheumatology, Zamora, Spain
  46. 46Hospital Severo Ochoa, Rheumatology, Madrid, Spain
  47. 47Hospital General de Elche, Rheumatology, Elche, Spain
  48. 48Hospital Son Llatzer, Rheumatology, Palma de Mallorca, Spain
  49. 49Hospital de Cabueñes, Rheumatology, Gijón, Spain
  50. 50Hospital de Valme, Rheumatology, Sevilla, Spain
  51. 51Consorci General de Valencia, Rheumatology, Valencia, Spain
  52. 52Hospital Doctor Negrín, Rheumatology, Gran Canaria, Spain
  53. 53Hospital Universitario de Castellón, Rheumatology, Castellón, Spain

Abstract

Background Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including giant cell arteritis (GCA) and Takayasu arteritis (TAK) (1-5). However, LVV-GCA and TAK show different demographic and clinical features that may influence on TCZ therapeutic response.

Objectives To compare the effectiveness of TCZ in patients with LVV-GCA and patients with TAK.

Methods Observational multicenter study of patients with LVV-GCA and TAK who received TCZ. Outcome variables were: a) proportion of patients who achieved complete clinical improvement along with normalization of laboratory markers (CRP ≤0.5mg/dL and/or ESR ≤ 20 mm/1st hour) at 12 months b) complete improvement in imaging techniques. A comparative study between patients with LVV-GCA and TAK was performed.

Results We evaluated 70 LVV-GCA and 57 TAK patients who received TCZ. Main clinical and demographic characteristic are described in Table 1. Patients with TAK were younger, had longer disease duration, had received more commonly previous biologic therapy and were receiving higher doses of prednisone at baseline. TCZ intravenous administration was more common in TAK patients (80.7% vs 48.6%; p<0.01). Follow-up time after TCZ onset was similar in both groups. At 12 months, about 75% of patients achieved complete clinical improvement and ESR/CRP normalization in both groups. A follow-up imaging technique was performed in 37 LVV-GCA patients after a mean time of 12.9±6.0 months and 38 TAK patients after 9.5±5.0 months. Complete improvement in imaging techniques was only observed in 18.9% and 21.1% of patients with LVV-GCA and TAK, respectively (Figure 1).

View this table:
Table 1.
Figure 1.
Figure 1.

Conclusion The effectiveness of TCZ was similar in patients with LVV-GCA and TAK, despite a more refractory disease in TAK patients. A discordance between clinical and imaging activity improvement was observed in both LVV-GCA and TAK, as reported in previous studies (3).

References [1]Calderón-Goercke M, et al. Semin Arthritis Rheum 2019; 49:126-35. https://doi.org/10.1016/j.semarthrit.2019.01.003

[2]Prieto-Peña D et al. Ther Adv Musculoskelet Dis. 2021;13:175. PMID: 34211589.

[3]Prieto Peña D et al. Clin Exp Rheumatol. 2021;39 Suppl 129:69-75. PMID: 33253103.

[4]González-Gay MA, et al. Expert Opin Biol Ther. 2019;19:65-72. doi: 10.1080/14712598.2019.1556256.

[5]Prieto-Peña D, et al. Semin Arthritis Rheum. 2019;48(4):720-727. doi: 10.1016/j.semarthrit.2018.05.007

Disclosure of Interests None declared

https://doi.org/10.1136/annrheumdis-2022-eular.2330

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.